James B Glavin Net Worth

What's James Glavin's mailing address?

James's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070.

Insiders trading at Nektar Therapeutics

Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, and John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.

What does Nektar Therapeutics do?

nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Nektar Therapeutics executives and stock owners

Nektar Therapeutics executives and other stock owners filed with the SEC include:

• Jonathan Zalevsky,
  Chief Research and Development Officer
• Howard Robin,
  President, Chief Executive Officer, Director
• Gilbert Labrucherie,
  Chief Financial Officer, Chief Operating Officer, Senior Vice President
• John Northcott,
  Senior Vice President and Chief Commercial Officer
• Howard W. Robin,
  CEO, Pres & Director
• Jillian Thomsen,
  Senior Vice President - Finance, Chief Accounting Officer
• Gilbert M. Labrucherie J.D.,
  Sr. VP, CFO & COO
• Dr. Jonathan Zalevsky,
  Chief R&D Officer
• John P. Northcott,
  Sr. VP & Chief Commercial Officer
• Mark A. Wilson,
  Sr. VP, Gen. Counsel & Sec.
• Myriam Curet,
  Independent Director
• Robert Chess,
  Independent Chairman of the Board
• Roy Whitfield,
  Lead Independent Director
• R. Scott Greer,
  Independent Director
• Karin Eastham,
  Independent Director
• Jeff Ajer,
  Independent Director
• Dr. Brian L. Kotzin,
  Sr. VP of Clinical Devel. & Head of Immunology
• Dr. Mary Tagliaferri L.Ac., M.D.,
  Sr. VP & Exec. Clinical Fellow
• Jennifer Ruddock,
  Sr. VP of Strategy & Corp. Affairs
• Robert Bacci,
  Sr. VP of HR and Facilities
• Jillian B. Thomsen,
  Sr. VP of Fin. & Chief Accounting Officer
• Lutz Lingnau,
  Director
• Dennis L Winger,
  Director
• Ivan P. Gergel,
  SVP Drug Development & CMO
• Maninder Hora,
  SVP Pharma Dev and Mfg
• Christopher A Kuebler,
  Director
• Joseph J Krivulka,
  Director
• Melvin Perelman,
  Director
• Ajit Gill,
  CEO & President
• Track Capital, Lp Deep Trac...,
  
• Randall W Moreadith,
  SVP Drug Development
• Bharat M Chowrira,
  COO & Head of PEGylation BU
• Robert Medve,
  Chief Medical Officer
• Nevan C Elam,
  General Counsel and Secretary
• Timothy Harkness,
  SVP & Chief Financial Officer
• John Stuart Patton,
  Chief Scientific Officer
• Irwin Lerner,
  Director
• Michael A/Ca Brown,
  Director
• Masuoka K. Lorianne,
  SVP & Chief Medical Officer
• Susan Wang,
  Director
• Rinko Ghosh,
  SVP & Chief Business Officer
• David Johnston,
  SVP, Research & Development
• Ajay Bansal,
  CFO, VP Finance & Admin
• Hoyoung Huh,
  Chief Operating Officer
• J Milton Harris,
  President of Nektar AL
• James B Glavin,
  Director
• John Nicholson,
  SVP & Chief Operating Officer
• Stephen K Doberstein,
  SVP & Chief Scientific Officer
• Gil M Labrucherie,
  SVP, COO & CFO
• Diana Brainard,
  Director
• Mark Andrew Wilson,
  Chief Legal Officer